Drug intelligence / Profile preview

VRP-019

Development stage: Preclinical
Lead developer: Venus Medicine Research Centre
Modality: Small Molecules
Administration: Topical

Overview

VRP-019 is a topical gel formulation of hypochlorous acid (HOCl) being developed by Venus Medicine Research Centre for wound care and the treatment of wound infections. Hypochlorous acid is a potent, naturally occurring antimicrobial agent produced by neutrophils during the oxidative burst to eliminate pathogens. As a therapeutic, HOCl acts as a broad-spectrum oxidant that rapidly destroys bacteria, fungi, and viruses by disrupting cell walls, denaturing proteins, and inhibiting essential enzymatic reactions. VRP-019 is currently in the early formulation and development (F&D) stage.

Other names: HOCl Gel

Beyond the preview

Go deeper on VRP-019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRP-019.

Explore the full profile